


Clinical Laserthermia Systems

Healthcare
Sweden


KEY DATA

Stock country	Sweden
Bloomberg	CLSB SS
Reuters	CLSRb.ST
Share price (close)	SEK 9.26
Free Float	100%
Market cap. (bn)	EUR 0.03/SEK 0.32
Website	https://clinicallaser.se
Next report date	

PERFORMANCE



VALUATION APPROACH



Source: Nordea estimates

ESTIMATE CHANGES

Year	2019E	2020E	2021E
Sales	-33%	-6%	-2%
EBIT (adj)	-12%	-6%	-12%

Source: Nordea estimates

Nordea Markets - Analysts

Klas Pyk
Analyst

Plans to initiate a large new clinical study

CLS posted sales of SEK 0.1m for Q1 2019, below our and the company's expectations. The operating loss amounted to SEK -9.9m versus SEK -1.4m in the same period last year. Q1 2018, however, was bolstered by a SEK ~6m payout from Horizon2020. During the quarter, CLS's joint product development project with Image Guided Therapy (IGT) was completed and the company aims to have the product ready for launch by H2 2019. In its report, CLS said that it is preparing to initiate a new clinical study involving around 100 patients to further validate the immunological effect of imILT. Given CLS's cash position of SEK 13.5m, we anticipate that the company will seek external financing shortly.

New sales force and product launch expected to support sales

CLS reported sales of SEK 0.1m for Q1, below our and the company's expectations (our forecast was SEK 0.5m). During the quarter, CLS's joint product development with IGT was completed. CLS will now file for FDA approval; assuming a timely process, it expects that it will have the product ready for launch in H2 2019. In addition, in its report, CLS said that MRI's sales force has now been adequately educated and that the distribution agreement has been in full effect since 1 April. We expect that both the new product launch and MRI's sales force will support sales going forward. Owing to slower-than-anticipated uptake in sales, however, we lower our 2019 revenue estimate to SEK 9m (14m).

Planning a new clinical study involving around 100 patients

In its report, CLS revealed that it is preparing to initiate a clinical study involving around 100 patients. The aim of the study is to further validate the immunological effect of imILT. We view potential additional validation as positive because it will likely increase confidence in imILT treatment. Clinical trials, however, are synonymous with high costs. As such, given CLS's cash position of SEK 13.5m at the end of the quarter, we expect the company to seek external financing shortly.

Estimate revisions

The slower-than-expected uptake in sales leads us to lower our full-year revenue estimates to SEK 9m (14m). We also incorporate favourable FX movements. We take down our DCF-based valuation range to SEK 9.4-11.2 (9.7-12.5) per share, only including current indications for which CLS has initiated sales. In our view, increased commercial activity and an expansion of the customer base are the key valuation triggers.

SUMMARY TABLE - KEY FIGURES

SEKm	2015	2016	2017	2018	2019E	2020E	2021E
Total revenue	0	4	11	8	9	57	124
EBITDA (adj)	-17	-27	-21	-33	-36	-23	4
EBIT (adj)	-17	-27	-21	-33	-38	-25	-7
EBIT (adj) margin	n.m.	-736.6%	-185.3%	-404.3%	-412.2%	-44.9%	-5.7%
EPS (adj)	-0.82	-1.14	-0.81	-1.04	-1.11	-0.74	-0.21
EPS (adj) growth	20.1%	-39.2%	29.1%	-28.1%	-6.6%	33.3%	71.7%
DPS (ord)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EV/Sales	n.a.	n.a.	n.a.	27.4	35.4	5.4	2.4
EV/EBIT (adj)	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.
P/E (adj)	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.
P/BV	n.a.	n.a.	n.a.	5.0	27.8	11.7	16.0
Dividend yield (ord)	n.a.	n.a.	n.a.	0.0%	0.0%	0.0%	0.0%
FCF Yield bef acq & disp	n.a.	n.a.	n.a.	-15.6%	-9.3%	-6.8%	1.3%
Net debt	-3	-6	-14	-23	7	-12	-16
Net debt/EBITDA	0.2	0.2	0.7	0.7	-0.2	0.5	-4.1
ROIC after tax	-87.2%	n.m.	n.m.	n.m.	n.m.	n.m.	-60.0%

Source: Company data and Nordea estimates


Quarterly review

CLS reported Q1 EBIT of SEK -9.9m versus SEK -1.4m for the same period last year. Q1 2018, however, was bolstered by a SEK ~6m payout from Horizon2020. Sales were below our and the company's expectations at SEK 0.1m (our estimate: SEK 0.5m). During the quarter, CLS's product development efforts came together with IGT, and the company will now file for FDA approval. The timing of the approval process is uncertain, but CLS aims to have the product ready for launch in H2 2019. In the report, CLS also announced that the company is planning to initiate a study involving 100 patients to further validate the immunological effects of imILT. At the end of the period, CLS reported a cash position of SEK 13.5m and, given the current burn rate, we anticipate that CLS will seek additional external financing shortly.

CLS posted a Q1 operating loss roughly in line with our expectations at SEK -9.9m, compared to SEK -1.4m last year. Last year's Q1, however, was positively impacted by a SEK ~6m payout from Horizon2020. Sales in the quarter were below our and the company's expectations at SEK 0.1m (our estimate: SEK 0.5m).


During the quarter, CLS's and IGT's joint development project was completed and the company will now file for 510(k) FDA approval. While the time for the approval process is uncertain, the company aims to have the product ready for launch in H2 2019. In addition, since 1 April, the distribution agreement with MRI Intervention has been fully in place. We anticipate that these collaborative agreements will support an uptick in sales going forward.

QUARTERLY REVENUE, SEKm



Source: Company data and Nordea

QUARTERLY OPEX, SEKm



Source: Company data and Nordea

Planning a new clinical study involving around 100 patients

In its report, CLS revealed that it is preparing to initiate a clinical study involving around 100 patients. The aim of the study is to further validate the immunological effect of imILT. We view this potential additional validation as positive because it will likely increase confidence in imILT treatment and thereby attract new customers. Clinical trials, however, are synonymous with high costs. As such, given CLS's cash position of SEK 13.5m at the end of the quarter, we expect the company to seek external financing shortly. We refrain from including the new study in our estimates before more information has been provided.

Another repeat order from the undisclosed US hospital

In March, CLS announced that it has received another repeat order for TRANBERG Laser Applicators from the undisclosed US hospital with which CLS has had an agreement since 2017. The order totals SEK ~0.1m. This is the fifth order that CLS has communicated publicly from the US hospital. According to CLS, the hospital uses TRANBERG products regularly for MR-guided laser ablations to treat painful non-malignant vascular malformations. In our view, repeat orders support the value proposition, but we consider increased commercial activity and an expansion of the customer base as stronger key valuation triggers.

CLS' main customers are the University of Texas Medical Branch and an undisclosed US hospital

ORDER HISTORY 2017 - Q1 2019

Announced in quarter	Amount, SEK	Description	Customer
Q1-17	250,000	Tranberg, Thermal System	Unannounced leading US hospital
Q2-17	50,000	Tranberg, Laser applicator	Unannounced leading US hospital
Q4-17	40,000	Consumables	University of Texas Medical Branch (UTMB)
Q4-17	100,000	Consumables	University of Texas Medical Branch (UTMB)
Q4-17	650,000	Consumables	UTMB, Desert Medical Imaging, Unannounced leading US hospital
Q1-18	55,000	Consumables	Laser Prostate Centers of America (LPCA)
Q1-18	240,000	Tranberg, Thermal System	University of Texas Medical Branch (UTMB)
Q2-18	400,000	Consumables	University of Texas Medical Branch (UTMB)
Q3-18	110,000	Tranberg, Laser Applicator	Unannounced leading US hospital
Q4-18	230,000	Consumables	University of Texas Medical Branch (UTMB) and Desert Medical Imaging
Q1-19	110,000	Tranberg, Laser Applicator	Unannounced leading US hospital

Source: Company data and Nordea

Aiming for product launch in H2 2019

Moving towards a complete solution for precision ablation

At the beginning of the year, CLS announced that it has entered into an agreement with Siemens Healthineers, giving CLS the right to license the "Access-i" software solution from the MedTech-giant; the goal is to connect and interface CLS's products with Siemens Healthineers' Magnetom Scanners. During the quarter, CLS, in collaboration with Image Guided Therapy (IGT), completed the development of an interface between CLS's products and the Siemens scanner. CLS now plans to file for 510(k) FDA approval. While the timeline for approval is uncertain, the company aims to have the product ready for launch in H2 2019.


CLS is also collaborating with MRI Interventions, a US-listed company that is commercialising the ClearPoint system, which enables a range of minimally invasive procedures in the brain using hospitals' existing MRI suites. Under the terms of the agreement, the two companies will co-develop a navigation and laser ablation platform for use in spine and neurosurgery treatment. MRI Interventions will receive the global licence and IP rights to current and future products in spine and neurosurgery, while CLS will hold exclusive manufacturing rights. A formal launch of the joint platform is expected in 2020, hence it will not have an impact on 2019 sales.

CLS and MRI have also entered into an exclusive distribution deal for the US and Canada, with CLS gaining access to a team of around 20 sales managers and clinical specialists. We believe CLS could benefit from MRI Interventions' established relationships and network of hospitals and clinicians through the installed ClearPoint base. According to a company presentation in February, ClearPoint is currently installed in 58 top US hospitals, and that number is growing. In its Q1 report, CLS said that the MRI's sales force has now been adequately educated and that the agreement has been in full effect since 1 April. We consider this as a positive step towards increasing commercial penetration and reaching profitability.

CLS strives towards offering a full product solution

Through its collaborations with MRI Interventions, Siemens and IGT, CLS strives towards offering a full product solution within minimally invasive surgery for its customers, offering both navigation and laser ablation to clinical specialists.

CLS PRODUCTS AND APPLICATIONS



Source: Company data

CLS attended ECIO

Spreading the word

CLS continued its marketing efforts in Q1, attending multiple conferences such as the European Conference on Interventional Oncology (ECIO) in Amsterdam and the UDRI - Fourth International Workshop on Diagnostic and Interventional Prostate MRI in Paris. During ECIO, CLS released a technical white paper which describes the company's imILT immuno-stimulating method. This white paper includes data from previous studies that CLS has conducted and compiles information that is primarily directed to doctors.

Strengthened IP protection

During the period, CLS was granted a new patent in China and received a positive preliminary notice in advance for another in Europe. The patent in China protects CLS's unique technology for temperature control during tumour treatments using imILT. Upon approval, the European patent will protect CLS in using cold fibre, in addition to non-cold fibre, in imILT treatment.

Estimate revisions

The slower-than-expected uptake in sales leads us to lower our full-year sales estimates to SEK 9m (14m), including a SEK ~4m payout from Horizon2020. We also incorporate favourable FX into our model. We take down our valuation range to SEK 9.4-11.2 (9.7-12.5) per share, only including current indications for which CLS has initiated sales. We see upside in the valuation range, however, if CLS demonstrates increased customer activity in other indications. In our view, increased commercial activity and an expansion of the customer base are the key valuation triggers.

Detailed estimates

QUARTERLY ESTIMATES

	Q1 2019	Q2 2019E	Q3 2019E	Q4 2019E	2019E
Net sales	0.1	0.3	1.0	3.9	5.3
Other operating income	0.1	4.0	0.0	0.0	4.1
Income	0.2	4.3	1.0	3.9	9.3
COGS	-0.1	-0.2	-0.6	-2.2	-3.0
Gross Profit	0.1	4.1	0.4	1.7	6.3
OPEX	-9.3	-10.5	-10.5	-11.8	-42.1
Depreciation and amortisation	-0.6	-0.6	-0.6	-0.6	-2.5
Other operating expenses	-0.1	-0.1	-0.1	-0.1	-0.4
Operating profit	-9.9	-7.0	-10.7	-10.8	-38.4
Net financials	0.37	-0.02	-0.02	-0.02	0.30
Profit before tax	-9.5	-7.0	-10.7	-10.8	-38.0
Tax	0.0	0.0	0.0	0.0	0.0
Profit for the period	-9.5	-7.0	-10.7	-10.8	-38.0

Source: Company data and Nordea estimates

Reported numbers and forecasts

INCOME STATEMENT

SEKm	2011	2012	2013	2014	2015	2016	2017	2018	2019E	2020E	2021E
Net revenue	n.a.	0	0	0	0	4	11	8	9	57	124
Revenue growth	n.a.	n.a.	-90.3%	-56.3%	n.m.	n.m.	208.5%	-26.6%	12.0%	512.1%	118.8%
of which organic	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
of which FX	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
EBITDA	0	-13	-18	-18	-17	-27	-21	-33	-36	-23	4
Depreciation and impairments PPE	0	0	0	0	0	0	0	0	-1	-1	-4
of which leased assets	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
EBITA	0	-13	-18	-18	-17	-27	-21	-33	-37	-24	0
Amortisation and impairments	0	0	0	0	0	0	0	0	-1	-2	-7
EBIT	n.a.	-13	-18	-18	-17	-27	-21	-33	-38	-25	-7
of which associates	0	0	0	0	0	0	0	0	0	0	0
Associates excluded from EBIT	0	0	0	0	0	0	0	0	0	0	0
Net financials	0	0	0	0	0	0	0	1	0	0	0
of which lease interest	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Changes in value, net	0	0	0	0	0	0	0	0	0	0	0
Pre-tax profit	0	-13	-18	-17	-17	-27	-21	-33	-38	-26	-7
Reported taxes	0	0	0	0	0	0	0	0	0	0	0
Net profit from continued operations	0	-13	-18	-17	-17	-27	-21	-33	-38	-26	-7
Discontinued operations	0	0	0	0	0	0	0	0	0	0	0
Minority interests	0	0	0	0	0	0	0	0	0	0	0
Net profit to equity	0	-13	-18	-17	-17	-27	-21	-33	-38	-26	-7
EPS	n.a.	-0.87	-1.16	-1.03	-0.82	-1.14	-0.81	-1.04	-1.11	-0.74	-0.21
DPS	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
of which ordinary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
of which extraordinary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Profit margin in percent

EBITDA	n.a.	n.m.	n.m.	n.m.	n.m.	-735.1%	-183.7%	-402.4%	-385.2%	-39.9%	3.3%
EBITA	n.a.	n.m.	n.m.	n.m.	n.m.	-736.6%	-185.3%	-402.8%	-398.2%	-41.9%	0.3%
EBIT	n.a.	n.m.	n.m.	n.m.	n.m.	-736.6%	-185.3%	-404.3%	-412.2%	-44.9%	-5.7%

Adjusted earnings

EBITDA (adj)	0	-13	-18	-18	-17	-27	-21	-33	-36	-23	4
EBITA (adj)	0	-13	-18	-18	-17	-27	-21	-33	-37	-24	0
EBIT (adj)	0	-13	-18	-18	-17	-27	-21	-33	-38	-25	-7
EPS (adj)	n.a.	-0.87	-1.16	-1.03	-0.82	-1.14	-0.81	-1.04	-1.11	-0.74	-0.21

Adjusted profit margins in percent

EBITDA (adj)	n.a.	n.m.	n.m.	n.m.	n.m.	-735.1%	-183.7%	-402.4%	-385.2%	-39.9%	3.3%
EBITA (adj)	n.a.	n.m.	n.m.	n.m.	n.m.	-736.6%	-185.3%	-402.8%	-398.2%	-41.9%	0.3%
EBIT (adj)	n.a.	n.m.	n.m.	n.m.	n.m.	-736.6%	-185.3%	-404.3%	-412.2%	-44.9%	-5.7%

Performance metrics

CAGR last 5 years											
Net revenue	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	146.8%	269.6%	346.2%	244.1%	102.4%
EBITDA	n.m.	n.m.	n.m.	n.m.	n.m.						
EBIT	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	n.m.
EPS	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	n.m.
DPS	n.m.	n.m.	n.m.	n.m.	n.m.						

Average last 5 years

Average EBIT margin	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	n.m.	-59.7%
Average EBITDA margin	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	n.m.	-51.7%

VALUATION RATIOS - ADJUSTED EARNINGS

SEKm	2011	2012	2013	2014	2015	2016	2017	2018	2019E	2020E	2021E
P/E (adj)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	n.m.
EV/EBITDA (adj)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	75.3
EV/EBITA (adj)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	978.3
EV/EBIT (adj)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	n.m.

VALUATION RATIOS - REPORTED EARNINGS

SEKm	2011	2012	2013	2014	2015	2016	2017	2018	2019E	2020E	2021E
P/E	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	n.m.
EV/Sales	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	27.42	35.36	5.43	2.45	
EV/EBITDA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	75.3
EV/EBITA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	978.3
EV/EBIT	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	n.m.
Dividend yield (ord.)	n.a.	0.0%	0.0%	0.0%	0.0%						
FCF yield	n.a.	-15.6%	-9.3%	-6.8%	1.3%						
FCF yield, adjusted for leases	n.a.	n.a.	n.a.	n.a.	n.a.						
Payout ratio	n.a.	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: Company data and Nordea estimates

BALANCE SHEET

SEKm	2011	2012	2013	2014	2015	2016	2017	2018	2019E	2020E	2021E
Intangible assets	0	12	14	17	18	20	24	26	25	26	25
of which R&D	0	0	0	0	0	0	0	0	0	0	0
of which other intangibles	0	12	14	17	18	20	24	26	25	26	25
of which goodwill	0	0	0	0	0	0	0	0	0	0	0
Tangible assets	0	0	0	0	0	0	1	1	0	0	0
of which leased assets	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Shares associates	0	0	0	0	0	0	0	0	0	0	0
Interest bearing assets	0	0	0	0	0	0	0	0	0	0	0
Deferred tax assets	0	0	0	0	0	0	0	0	0	0	0
Other non-IB non-current assets	0	0	0	0	0	0	0	0	0	0	0
Other non-current assets	0	0	0	0	0	0	0	0	0	0	0
Total non-current assets	0	12	14	17	19	20	25	27	25	26	25
Inventory	0	0	0	0	0	0	3	5	1	16	36
Accounts receivable	0	0	0	0	0	0	0	0	0	9	22
Short-term leased assets	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Other current assets	0	1	1	2	1	1	1	2	2	6	14
Cash and bank	0	7	14	19	3	6	16	24	0	20	23
Total current assets	0	8	15	20	4	7	20	31	4	51	95
Assets held for sale	0	0	0	0	n.a.						
Total assets	0	20	29	37	22	27	45	58	29	77	120
Shareholders equity	0	17	26	32	19	17	33	50	12	27	20
Of which preferred stocks	0	0	0	0	0	0	0	0	0	0	0
Of which equity part of hybrid debt	0	0	0	0	0	0	0	0	0	0	0
Minority interest	0	0	0	0	0	0	0	0	0	0	0
Total Equity	0	17	26	32	19	17	33	50	12	27	20
Deferred tax	0	0	0	0	0	0	0	0	0	0	0
Long term interest bearing debt	0	0	0	0	0	0	1	1	7	7	7
Pension provisions	0	0	0	0	0	0	0	0	0	0	0
Other long-term provisions	0	0	0	0	0	0	0	0	0	0	0
Other long-term liabilities	0	0	0	0	0	0	0	0	0	0	0
Non-current lease debt	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Convertible debt	0	0	0	0	0	0	0	0	0	0	0
Shareholder debt	0	0	0	0	0	0	0	0	0	0	0
Hybrid debt	0	0	0	0	0	0	0	0	0	0	0
Total non-current liabilities	0	0	0	0	0	0	1	1	7	7	7
Short-term provisions	0	0	0	0	0	0	0	0	0	0	0
Accounts payable	0	2	2	4	2	3	3	5	6	14	30
Current lease debt	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Other current liabilities	0	1	1	1	1	7	7	2	4	28	62
Short term interest bearing debt	0	0	0	0	0	0	0	0	0	0	0
Total current liabilities	0	3	3	5	3	10	11	7	10	42	92
Liabilities for assets held for sale	0	0	0	0	0	0	0	0	0	0	0
Total liabilities and equity	0	20	29	37	22	27	45	58	29	77	120
Balance sheet and debt metrics											
Net debt	0	-7	-14	-19	-3	-6	-14	-23	7	-12	-16
of which lease debt	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Working capital	0	-2	-2	-4	-2	-9	-5	0	-7	-11	-21
Invested capital	0	10	13	13	17	11	19	27	19	15	4
Capital employed	0	17	26	32	19	17	34	51	19	35	27
ROE	n.m.	n.m.	-84.9%	-60.7%	-65.0%	n.m.	-84.9%	-79.4%	n.m.	n.m.	-30.5%
ROIC	n.m.	n.m.	n.m.	n.m.	-87.2%	n.m.	n.m.	n.m.	n.m.	n.m.	-60.0%
ROCE	n.a.	-74.2%	-69.6%	-55.7%	-85.3%	n.m.	-60.7%	-65.3%	n.m.	-73.8%	-26.3%
Net debt/EBITDA	n.m.	0.6	0.7	1.1	0.2	0.2	0.7	0.7	-0.2	0.5	-4.1
Interest coverage	n.a.	n.m.									
Equity ratio	n.m.	85.2%	89.4%	85.4%	87.4%	62.5%	73.4%	85.8%	39.6%	35.6%	16.8%
Net gearing	n.m.	-40.6%	-51.8%	-59.2%	-13.5%	-36.3%	-41.9%	-46.2%	62.8%	-45.4%	-81.9%

Source: Company data and Nordea estimates

CASH FLOW STATEMENT

SEKm	2011	2012	2013	2014	2015	2016	2017	2018	2019E	2020E	2021E
EBITDA (adj) for associates	0	-13	-18	-18	-17	-27	-21	-33	-36	-23	4
Paid taxes	0	0	0	0	0	0	0	0	0	0	0
Net financials	0	0	0	0	0	0	0	1	0	0	0
Change in provisions	0	0	0	0	0	0	0	0	0	0	0
Change in other LT non-IB	0	0	0	0	0	0	0	0	0	0	0
Cash flow to/from associates	0	0	0	0	0	0	0	0	0	0	0
Dividends paid to minorities	0	0	0	0	0	0	0	0	0	0	0
Other adj to reconcile to cash flow	0	0	0	0	0	0	0	0	0	0	0
Funds from operations (FFO)	0	-13	-18	-18	-17	-27	-21	-33	-36	-23	4
Change in NWC	0	1	0	2	-2	7	-3	-5	7	4	10
Cash flow from operations (CFO)	0	-12	-18	-16	-19	-20	-24	-38	-29	-18	14
Capital expenditure	0	-2	-2	-2	-2	-2	-5	-1	-1	-3	-10
Free cash flow before A&D	0	-14	-21	-18	-21	-21	-29	-39	-30	-22	4
Proceeds from sale of assets	0	0	0	0	0	0	0	0	0	0	0
Acquisitions	0	0	0	0	0	0	0	0	0	0	0
Free cash flow	0	-14	-21	-18	-21	-21	-29	-39	-30	-22	4
Free cash flow, adjusted for leases	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Dividends paid	0	0	0	0	0	0	0	0	0	0	0
Equity issues / buybacks	0	19	27	23	4	25	37	43	0	41	0
Net change in debt	0	0	0	0	0	0	2	0	6	0	0
Other financing adjustments	0	0	0	0	0	0	0	0	0	0	0
Other non-cash adjustments	0	2	0	0	0	0	0	6	0	0	0
Change in cash	0	7	6	5	-16	4	9	9	-24	19	4
Cash flow metrics											
Capex/D&A	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	29.6%	n.m.	88.9%
Capex/Sales	n.a.	n.m.	n.m.	n.m.	n.m.	42.2%	41.5%	12.0%	8.0%	6.0%	8.0%
Key information											
Share price year end (/current)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	7	9	9	9
Market cap.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	250	320	320	320
Enterprise value	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	227	328	308	304
Diluted no. of shares, year-end (m)	0.0	14.6	17.0	17.0	23.4	23.8	28.7	34.6	34.6	34.6	34.6

Source: Company data and Nordea estimates

Disclaimer and legal disclosures

Origin of the report

This publication or report originates from: Nordea Bank Abp, including its branches Nordea Danmark, Filial af Nordea Bank Abp, Finland, Nordea Bank Abp, filial i Norge and Nordea Bank Abp, filial i Sverige (together "Nordea") acting through their unit Nordea Markets.

Nordea Bank Abp is supervised by the European Central Bank and the Finnish Financial Supervisory Authority and the branches are supervised by the European Central Bank and the Finnish Financial Supervisory Authority and the Financial Supervisory Authorities in their respective countries.

Content of report

This report has been prepared solely by Nordea Markets.

Opinions or suggestions from Nordea Markets credit and equity research may deviate from one another or from opinions presented by other departments in Nordea. This may typically be the result of differing time horizons, methodologies, contexts or other factors.

The information provided herein is not intended to constitute and does not constitute investment advice nor is the information intended as an offer or solicitation for the purchase or sale of any financial instrument. The information contained herein has no regard to the specific investment objectives, the financial situation or particular needs of any particular recipient. Relevant and specific professional advice should always be obtained before making any investment or credit decision.

Opinions or ratings are based on one or more methods of valuation, for instance cash flow analysis, use of multiples, behavioural technical analyses of underlying market movements in combination with considerations of the market situation and the time horizon. Key assumptions of forecasts or ratings in research cited or reproduced appear in the research material from the named sources. The date of publication appears from the research material cited or reproduced. Opinions and estimates may be updated in subsequent versions of the report, provided that the relevant company/issuer is treated anew in such later versions of the report.

Validity of the report

All opinions and estimates in this report are, regardless of source, given in good faith, and may only be valid as of the stated date of this report and are subject to change without notice.

No individual investment or tax advice

The report is intended only to provide general and preliminary information to investors and shall not be construed as the basis for any investment decision. This report has been prepared by Nordea Markets as general information for private use of investors to whom the report has been distributed, but it is not intended as a personal recommendation of particular financial instruments or strategies and thus it does not provide individually tailored investment advice, and does not take into account the individual investor's particular financial situation, existing holdings or liabilities, investment knowledge and experience, investment objective and horizon or risk profile and preferences. The investor must particularly ensure the suitability of an investment as regards his/her financial and fiscal situation and investment objectives. The investor bears the risk of losses in connection with an investment.

Before acting on any information in this report, it is recommendable to consult (without being limited to) one's financial, legal, tax, accounting, or regulatory advisor in any relevant jurisdiction.

The information contained in this report does not constitute advice on the tax consequences of making any particular investment decision. Each investor shall make his/her own appraisal of the tax and other financial merits of his/her investment.

Sources

This report may be based on or contain information, such as opinions, estimates and valuations which emanate from: Nordea Markets' analysts or representatives, publicly available information, information from other units of Nordea, or other named sources.

To the extent this publication or report is based on or contain information emanating from other sources ("Other Sources") than Nordea Markets ("External Information"), Nordea Markets has deemed the Other Sources to be reliable but neither Nordea, others associated or affiliated with Nordea nor any other person, do guarantee the accuracy, adequacy or completeness of the External Information.

Limitation of liability

Nordea or other associated and affiliated companies assume no liability as regards to any investment, divestment or retention decision taken by the investor on the basis of this report. In no event will Nordea or other associated and affiliated companies be liable for direct, indirect or incidental, special or consequential damages (regardless of whether being considered as foreseeable or not) resulting from the information in this report.

Risk information

The risk of investing in certain financial instruments, including those mentioned in this report, is generally high, as their market value is exposed to a lot of different factors such as the operational and financial conditions of the relevant company, growth prospects, change in interest rates, the economic and political environment, foreign exchange rates, shifts in market sentiments etc. Where an investment or security is denominated in a different currency to the investor's currency of reference, changes in rates of exchange may have an adverse effect on the value, price or income of or from that investment to the investor. Past performance is not a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. When investing in individual shares, the investor may lose all or part of the investments.

Conflicts of interest

Readers of this document should note that Nordea Markets has received remuneration from the company mentioned in this document for the production of the report. The remuneration is not dependent on the content of the report.

Nordea, affiliates or staff in Nordea, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives) of any company mentioned in the report.

To limit possible conflicts of interest and counter the abuse of inside knowledge, the analysts of Nordea Markets are subject to internal rules on sound ethical conduct, the management of inside information, handling of unpublished research material, contact with other units of Nordea and personal account dealing. The internal rules have been prepared in accordance with applicable legislation and relevant industry standards. The object of the internal rules is for example to ensure that no analyst will abuse or cause others to abuse confidential information. It is the policy of Nordea Markets that no link exists between revenues from capital markets activities and individual analyst remuneration. Nordea and the branches are members of national stockbrokers' associations in each of the countries in which Nordea has head offices. Internal rules have been developed in accordance with recommendations issued by the stockbrokers associations. This material has been prepared following the Nordea Conflict of Interest Policy, which may be viewed at www.nordea.com/mifid.

Distribution restrictions

The securities referred to in this report may not be eligible for sale in some jurisdictions. This report is not intended for, and must not be distributed to private customers in the UK or the US. This research report is intended only for, and may be distributed only to, accredited investors, expert investors or institutional investors in Singapore who may contact Nordea Bank, Singapore Branch of 138 Market Street, #09-01 CapitaGreen, Singapore 048946.

This report may be distributed by Nordea Bank Luxembourg S.A., 562 rue de Neudorf, L-2015 Luxembourg which is subject to the supervision of the Commission de Surveillance du Secteur Financier.

This publication or report may be distributed by Nordea Bank Abp Singapore Branch, which is subject to the supervision of the European Central Bank, the Finnish Financial Supervisory Authority and the Monetary Authority of Singapore.

This publication or report may be distributed in the UK to institutional investors by Nordea Bank Abp London Branch of 6th Floor, 5 Aldermanbury Square, London, EC2V 7AZ, which is under supervision of the European Central Bank, Finanssivalvonta (Financial Supervisory Authority) in Finland and subject to limited regulation by the Financial Conduct Authority and Prudential Regulation Authority in the United Kingdom. Details about the extent of our regulation by the Financial Conduct Authority and Prudential Regulation Authority are available from us on request.

This report may not be mechanically duplicated, photocopied or otherwise reproduced, in full or in part, under applicable copyright laws.

Analyst Shareholding

Nordea Markets analysts do not hold shares in the companies that they cover. No holdings or other affiliations by analysts or associates.

Fair value sensitivity

We calculate our fair values by weighting DCF, DDM, SOTP, asset-based and other standard valuation methods. When applicable, we set a 12-month target price by applying an appropriate premium/discount and/or other relevant adjustment to our fair value to reflect the share price potential we see within the coming 12 months. Our fair values are sensitive to changes in valuation assumptions, of which growth, margins, tax rates, working capital ratios, investment-to-sales ratios and cost of capital are typically the most sensitive.

It should be noted that our fair values would change by a disproportionate factor if changes are made to any or all valuation assumptions, owing to the non-linear nature of the standard valuation models applied (mentioned above). As a consequence of the standard valuation models we apply, changes of 1-2 percentage points in any single valuation assumption can change the derived fair value by as much as 30% or more. Dividend payouts are included in the target price. All research is produced on an ad hoc basis and will be updated when the circumstances require it.

Marketing Material

This research report should be considered marketing material, as it has been commissioned and paid for by the subject company, and has not been prepared in accordance with the regulations designed to promote the independence of investment research and it is not subject to any legal prohibition on dealing ahead of the dissemination of the report. However, Nordea Markets analysts are according to internal policies not allowed to hold shares in the companies/sectors that they cover.

Where applicable, recommendation changes are available at: <https://research.nordea.com/compliance#equity-changes>.

Market-making obligations and other significant financial interest

Nordea Markets has no market-making obligations in Clinical Laserthermia Systems.

Investment banking transactions

In view of Nordea's position in its markets readers should assume that the bank may currently or may in the coming three months and beyond be providing or seeking to provide confidential investment banking services to the company/companies

Issuer Review

This report has not been reviewed by the Issuer prior to publication.

Completion Date

24 May 2019, 02:30 CET

Nordea Bank Abp	Nordea Bank Abp, filial i Sverige	Nordea Danmark, Filial af Nordea Bank Abp, Finland	Nordea Bank Abp, filial i Norge
Nordea Markets Division, Research Visiting address: Aleksis Kiven katu 7, Helsinki FI-00020 Nordea Finland Tel: +358 9 1651 Fax: +358 9 165 59710	Nordea Markets Division, Research Visiting address: Smålandsgatan 17 SE-105 71 Stockholm Sweden Tel: +46 8 614 7000 Fax: +46 8 534 911 60	Nordea Markets Division, Research Visiting address: Grønjordsvej 10 DK-2300 Copenhagen S Denmark Tel: +45 3333 3333 Fax: +45 3333 1520	Nordea Markets Division, Research Visiting address: Essendrops gate 7 N-0107 Oslo Norway Tel: +47 2248 5000 Fax: +47 2256 8650
Reg.no. 2858394-9 Satamaradankatu 5 Helsinki			